J. Andrew Livingston

J. Andrew Livingston is an Associate Professor at The University of Texas MD Anderson Cancer Center, where he specializes in oncology, sarcoma, and radiation oncology. His research focuses on adolescent and young adult cancer care, including metastatic recurrence drivers, early mortality risk, and physical activity monitoring in this population. He has published extensively on TFCP2 fusion-positive rhabdomyosarcomas, pathologic response to neoadjuvant radiotherapy with immune-checkpoint blockade in undifferentiated pleomorphic sarcoma, and phase II trials of olaparib with ceralasertib in recurrent osteosarcoma. His work integrates pathology, immunology, and cancer treatment outcomes, with recent findings appearing in JAMA Oncology, Journal of Clinical Oncology, and ESMO Open.